Table 2.
Genotype | n (%) | sTNF-RI (pg/ml) | sTNF-RII (pg/ml) |
Early RA | |||
AA | 41 (39.8) | 1,543 ± 597 | 4,435 ± 1,898 |
AG | 50 (48.5) | 1,426 ± 629 | 4,302 ± 1,672 |
GG | 12 (11.7) | 1,303 ± 447 | 4,566 ± 1,490 |
Established RA | |||
AA | 48 (31.8) | 1,827 ± 758 | 5,740 ± 1,942 |
AG | 70 (46.4) | 1,688 ± 674 | 5,475 ± 2,020 |
GG | 33 (21.8) | 1,757 ± 559 | 5,857 ± 2,393 |
Shown are tumor necrosis factor receptor I (TNF-RI) A36G single nucleotide polymorphism genotype frequencies and soluble tumor necrosis factor receptor (sTNFR) levels in rheumatoid arthritis (RA) patients with early (n = 103) and established (n = 151) disease. sTNFR levels are expressed as the mean ± standard deviation. No significant differences in sTNFR levels were found between any of the genotypes in either population. sTNF-RII, soluble tumor necrosis factor receptor II.